Recently  has been presented in a single pill combination of antiplatelet (aspirin), statins (atorvastatin) and ACE inhibitors (ramipril).

   These known and classic products have been and will be the mainstay of treatment of vascular mainly in secondary prevention after stroke or ischemic vascular or periphera;l or primary prevention in patients with significant risk factors for vascular disease.

   The ease of combining into a single pill the three components is not new and it seems obvious useful  (increased compliance, avoiding abandonment, etc …). The reason that has not been done so far does not respond to business problems as might be expected whether galenic problems, given the instability of the components, to join them lose some of their pharmacochemical properties. Finally getting a single pill “partitioned” where the different components are joined avoids these problems.

   A curiosity is the dose of the product components: AAS 100 mg, 20 mg and atorvatatina and ramipril 5 or 10 mg. The asprin is the most widely used antiplatelet neurology, although often used in acute phase 300 mg / day dose of 100 mg / day is becoming more taken after clinical stability and low risk patients and chronic use. The dose of atorvastatin is the most used and applied in the treatment of a patient with high cardiovascular risk (LDL cholesterol guidelines recommend remember. By the effectiveness of the evening dose of statin should be given “Trinomia” at dinner.

   Finally ramipril for its pleiotropic effects, safety and half-time seems best suited ACE inhibitors, given its beneficial effects in reduction of ischemic vascular events in cardiac pathology.

   It will certainly be a good choice in follow-up of a patient with non-cardioembolic stroke and vascular risk factors or atherothrombotic etiololgy.

    The presentation of this Polycap was conducted by the Spanish cardiologist Valenti Fuster recently. New pills with atrovastatin 40 mg are just ready in other countries.